The 36-month beta value for NSPR is at 0.89. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NSPR is 15.02M, and currently, shorts hold a 0.60% of that float. The average trading volume for NSPR on April 03, 2024 was 23.74K shares.
NSPR) stock’s latest price update
InspireMD Inc (NASDAQ: NSPR)’s stock price has dropped by -9.16 in relation to previous closing price of 2.37. Nevertheless, the company has seen a loss of -6.93% in its stock price over the last five trading days. GlobeNewsWire reported 2024-02-28 that -Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2023 financial results on Wednesday, March 6th, 2024, before the financial markets open.
NSPR’s Market Performance
InspireMD Inc (NSPR) has experienced a -6.93% fall in stock performance for the past week, with a -19.17% drop in the past month, and a -23.49% drop in the past quarter. The volatility ratio for the week is 8.14%, and the volatility levels for the past 30 days are at 7.09% for NSPR. The simple moving average for the past 20 days is -11.09% for NSPR’s stock, with a -25.54% simple moving average for the past 200 days.
Analysts’ Opinion of NSPR
Many brokerage firms have already submitted their reports for NSPR stocks, with Rodman & Renshaw repeating the rating for NSPR by listing it as a “Buy.” The predicted price for NSPR in the upcoming period, according to Rodman & Renshaw is $4 based on the research report published on January 07, 2016 of the previous year 2016.
Oppenheimer gave a rating of “Outperform” to NSPR, setting the target price at $6 in the report published on November 26th of the previous year.
NSPR Trading at -18.96% from the 50-Day Moving Average
After a stumble in the market that brought NSPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.16% of loss for the given period.
Volatility was left at 7.09%, however, over the last 30 days, the volatility rate increased by 8.14%, as shares sank -16.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.65% lower at present.
During the last 5 trading sessions, NSPR fell by -6.93%, which changed the moving average for the period of 200-days by +8.04% in comparison to the 20-day moving average, which settled at $2.40. In addition, InspireMD Inc saw -23.49% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NSPR starting from ROUBIN GARY S, who purchase 50,000 shares at the price of $2.53 back on Nov 30 ’23. After this action, ROUBIN GARY S now owns 438,902 shares of InspireMD Inc, valued at $126,540 using the latest closing price.
Stuka Paul, the Director of InspireMD Inc, purchase 175,000 shares at $1.63 during a trade that took place back on May 12 ’23, which means that Stuka Paul is holding 248,534 shares at $285,722 based on the most recent closing price.
Stock Fundamentals for NSPR
Current profitability levels for the company are sitting at:
- -3.41 for the present operating margin
- 0.29 for the gross margin
The net margin for InspireMD Inc stands at -3.19. The total capital return value is set at -0.51. Equity return is now at value -70.01, with -55.10 for asset returns.
Based on InspireMD Inc (NSPR), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -10.27.
Currently, EBITDA for the company is -20.66 million with net debt to EBITDA at 0.38. When we switch over and look at the enterprise to sales, we see a ratio of 6.83. The receivables turnover for the company is 2.53for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.34.
Conclusion
In conclusion, InspireMD Inc (NSPR) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
